Abstract
An artificial double tandem tumor-specific promoter based on survivin and human telomerase reverse transcriptase gene promoters was constructed. Studies in in vitro and ex vivo therapeutic systems showed that the designed promoter exhibits a high activity in tumor cells, which is comparable to the activity of the CMV constitutive promoter.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hsu, C.P., Miaw, J., Hsia, J.Y., Shai, S.E., and Chen, C.Y., Concordant expression of the telomeraseassociated genes in non-small cell lung cancer, Eur. J. Surg. Oncol., 2003, vol. 29, pp. 594–599.
Poulsen, T.T., Pedersen, N., Juel, H., and Poulsen, H.S., A chimeric fusion of the hASH1 and EZH2promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells, Cancer Gene Ther., 2008, vol. 15, pp. 563–575.
Farokhimanesh, S., Rahbarizadeh, F., Rasaee, M.J., Kamali, A., and Mashkani, B., Hybrid promoters directed tbid gene expression to breast cancer cells by transcriptional targeting, Biotech. Prog., 2010, vol. 26, pp. 505–511.
Kim, H.A., Park, J.H., Yi, N., and Lee, M., Delivery of hypoxia and glioma dual-specific suicide gene using dexamethasone conjugated polyethylenimine for glioblastoma- specific gene therapy, Mol. Pharm., 2014, vol. 11, pp. 938–950.
Alekseenko, I.V., Pleshkan, V.V., Kopantzev, E.P., Stukacheva, E.A., Chernov, I.P., Vinogradova, T.V., and Sverdlov, E.D., Activity of the upstream component of tandem tert/survivin promoters depends on features of the downstream component, PLoS One, 2012, vol. 7, e46474.
Kerr, D., Clinical development of gene therapy for colorectal cancer, Nat. Rev. Cancer, 2003, vol. 3, pp. 615–622.
Freeman, S.M., Abboud, C.N., Whartenby, K.A., Packman, C.H., Koeplin, D.S., Moolten, F.L., and Abraham, G.N., The “bystander effect:” tumor regression when a fraction of the tumor mass is genetically modified, Cancer Res., 1993, vol. 53, pp. 5274–5283.
Mori, K., Iwata, J., Miyazaki, M., Osada, H., Tange, Y., Yamamoto, T., Aiko, Y., Tamura, M., and Shiroishi, T., Bystander killing effect of tymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells, Neurol. Med. Chir. (Tokyo), 2010, vol. 50, pp. 545–553.
Yamamoto, S., Yamano, T., Tanaka, M., Hoon, D.S., Takao, S., Morishita, R., Aikou, T., and Kaneda, Y., A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma, Cancer Gene Ther., 2003, vol. 10, pp. 179–186.
Azatian, A., Yu, H., Dai, W., Schneiders, F.I., Botelho, N.K., and Lord, R.V., Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas, J. Gastrointest. Surg., 2009, vol. 13, pp. 1044–1051.
Clive, K.S., Tyler, J.A., Clifton, G.T., Holmes, J.P., Mittendorf, E.A., Ponniah, S., and Peoples, G.E., Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?, Expert Rev. Vaccines, 2010, vol. 9, pp. 519–525.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © I.V. Alekseenko, V.V. Pleshkan, A.V. Sass, O.B. Filyukova, E.V. Snezhkov, E.D. Sverdlov, 2018, published in Doklady Akademii Nauk, 2018, Vol. 480, No. 5, pp. 609–612.
Rights and permissions
About this article
Cite this article
Alekseenko, I.V., Pleshkan, V.V., Sass, A.V. et al. A Universal Tumor-Specific Promoter for Cancer Gene Therapy. Dokl Biochem Biophys 480, 158–161 (2018). https://doi.org/10.1134/S1607672918030092
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1607672918030092